Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma

Mostrar otras versiones (1)

The PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL‐302 is a novel highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL‐302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong cand...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohlin, Sofie, Hansson, Karin, Radke, Katarzyna, Martinez, Sonia, Blanco‐Apiricio, Carmen, Garcia‐Ruiz, Cristian, Welinder, Charlotte, Esfandyari, Javanshir, O'Neill, Michael, Pastor, Joaquin, von Stedingk, Kristoffer, Bexell, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685085/
https://www.ncbi.nlm.nih.gov/pubmed/31310053
http://dx.doi.org/10.15252/emmm.201810058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685085/
https://www.ncbi.nlm.nih.gov/pubmed/31310053
http://dx.doi.org/10.15252/emmm.201810058

Ejemplares similares